Chippenham-based healthcare group Alliance Pharma has completed the acquisition of silicone-based scar treatment brand ScarAway in the US.
Alliance bought ScarAway, as well as the rights to sell Kelo-cote, from Perrigo for $19.4m.
ScarAway is the leading silicone-based scar treatment, and the second-largest scar treatment brand in the US with net 12-month sales of around $10m and market share of 28 per cent.
The US is the second-largest global market for scar treatments with an estimated current retail value of around $90m per annum. Peter Butterfield, CEO of Alliance, said: "I'm delighted to have completed such a strategically important and earnings enhancing acquisition for Alliance which creates our first fully global brand in Kelo-cote."